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Abstract Increased amyloid- precursor protein (APP)
and amyloid- (A) accumulation appear to be upstream
steps in the pathogenesis of sporadic inclusion-body myosi-
tis (s-IBM). BACE1, participating in A production is also
increased in s-IBM muscle Wbers. Nogo-B and Nogo-A
belong to a family of integral membrane reticulons, and
Nogo-B binding to BACE1 blocks BACE1 access to APP,
decreasing A production. We studied Nogo-B and Nogo-
A in s-IBM muscle and in our IBM muscle culture models,
based on APP-overexpression or ER-stress-induction in
cultured human muscle Wbers (CHMFs). We report that: (1)
in biopsied s-IBM Wbers, Nogo-B is increased, accumulates
in aggregates, is immuno-co-localized with BACE1, and
binds to BACE1; Nogo-A is undetectable. (2) In CHMFs,
(a) APP overexpression increases Nogo-B, Nogo-A, and
BACE1, (b) ER stress increases BACE1 but decreases
Nogo-B and Nogo-A, (c) Nogo-B and Nogo-A associate
with BACE1. Accordingly, two novel mechanisms, APP
overexpression and ER stress, are involved in Nogo-B and
Nogo-A expression in human muscle. We propose that in
s-IBM muscle the Nogo-B increase may represent an
attempt by muscle Wber to decrease A production. How-
ever, the increase of Nogo-B seems insuYcient because A
continues to accumulate and the disease progresses. We
propose that manipulations, which increase Nogo-B in s-IBM
muscle might oVer a new therapeutic opportunity.
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Introduction
Sporadic inclusion-body myositis (s-IBM) is the most com-
mon, relentlessly progressive muscle disease of older per-
sons. It leads to severe muscle wasting and disability, and
there is no persistently successful treatment [14]. Both,
degeneration of muscle Wbers and mononuclear cell inXam-
mation are components of s-IBM muscle biopsy pathology
[reviewed in 9, 13]. Degeneration of s-IBM muscle Wbers
includes vacuolization, accompanied by intra-muscle-Wber
accumulations of congophilic, ubiquitinated, multi-protein
aggregates, which include amyloid- (A) and paired heli-
cal Wlaments (PHFs) containing phosphorylated tau (p-tau)
[8, 9]. An intriguing aspect is that the molecular-morphologic
phenotype of s-IBM muscle is similar to Alzheimer-disease
(AD) brain [8, 9] including, in addition to accumulated
A and p-tau, accumulations of several other “Alzheimer-
characteristic” proteins, markers of oxidative stress, and
mitochondrial abnormalities [8, 9]. Endoplasmic reticulum
stress and proteasome inhibition were also recently shown
to be components of the s-IBM pathogenesis [15, 37].
Along with accumulated A, there are increased transcrip-
tion and accumulation of amyloid- precursor protein
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518 Acta Neuropathol (2007) 114:517–526(APP) [3, 28]. BACE1 (-site of the APP cleaving
enzyme) [23] and components of -secretase—presenilin 1
and nicastrin [38]—are also increased [7, 34–36] and are
known to participate in abnormal processing of APP and
A production. Several lines of evidence based on the IBM
human muscle culture model and various transgenic mouse
models [16, 20, 21, 31], strongly suggest that intra-muscle-
Wber accumulation of APP and of its proteolytic fragment
A plays a key upstream toxic role in s-IBM pathogenesis
[5, 6, 8, 9, 15, 24, 41, 43]. Accordingly, we postulate that
methods reducing A accumulation in s-IBM muscle Wbers
could beneWt s-IBM patients.
In vitro Nogo-B and RTN3 interact with BACE1 to
block BACE1 access to APP resulting in decreased A
production [18]. Nogo, also known as reticulon 4 (RTN4),
belongs to the reticulon (RTN) family of integral mem-
brane proteins [32, 44]. All RTNs, including members of
the Nogo family, share a common C-terminal domain but
diVer in the length of their N-terminal domains [32, 44].
Nogo-A (RTN4A), Nogo-B (RTN4B) and Nogo-C (RTN4C)
are the three main isoforms of RTN4 [44]. They are
encoded by the same gene, and their variants, generated
by alternative splicing or alternative promoter usage, are
diVerentially distributed in various tissues [25, 32, 44].
RTNs are especially abundant in the endoplasmic reticulum
[32, 44]. Nogo-B has also been reported in cell surface
caveolae/lipid rafts [1]. Nogo-A has been reported to partic-
ipate in several neurodegenerative disorders [reviewed in
44], and recently it was shown accumulated in the A-con-
taining senile plaques of Alzheimer-disease brains [17].
We examined Nogo-B, Nogo-A and RTN3 in s-IBM
muscle Wbers by immunoblotting and immunomorphologic
techniques, and evaluated whether they physically associate
with BACE1. To explore the possible pathogenic mecha-
nisms involved in Nogo regulation in s-IBM, we utilized
our established experimentally-induced IBM culture human
muscle models, based either on overexpression of APP
through an adenovirus mediated APP gene transfer, or by
induction of ER stress [5, 6, 24, 26, 27].
Materials and methods
Muscle biopsies
Studies were performed on diagnostic muscle biopsies
obtained with informed consent from 37 patients with the
following diagnoses: 14 s-IBM; 4 polymyositis; 2 dermato-
myositis; 3 vacuolated non-IBM myopathies (including 2
acid-maltase deWciency patients and 1 vacuolar myopathy
of unknown origin); 4 peripheral neuropathies; and 10
normal muscles (no detectable neuromuscular disease). All
s-IBM biopsies met the diagnostic criteria detailed in [8].
Immunoblots
Immunoblots of s-IBM and control muscle biopsies were
performed as previously described [15, 26, 37, 40]. In brief,
20 m-thick frozen muscle sections were collected at
¡25°C and rapidly homogenized on ice in RIPA buVer and
protease inhibitor cocktail (Roche Diagnostic GmBH,
Mannheim, Germany). Twenty microgram of total muscle
protein were electrophoresed in NuPage 3–8% Tris–acetate
gel and 1X Tris–acetate SDS running buVer. They were
then transferred to a nitrocellulose membrane and incu-
bated with a primary antibody overnight at 4°C. The fol-
lowing well-characterized antibodies against Nogo were
used: (a) rabbit polyclonal antibody R461, recognizing
Nogo-A/B on immunoblots [18]; (b) goat polyclonal anti-
body N-18, also recognizing Nogo-A/B [1, 17]; and (c)
rabbit polyclonal antibody H-300, recognizing an epitope
exclusively present on the N-terminal of Nogo-A [30]. Fur-
ther, a rabbit polyclonal antibody R454, recognizing RTN3
[18], was also used in preliminary experiments. BACE1
was studied with a mouse monoclonal antibody, clone 61–3E7
[18], and a rabbit polyclonal antibody. Table 1 lists all the
antibodies, their dilutions and sources.
After incubation in a primary antibody, membranes were
washed and incubated with an appropriate species-speciWc
secondary antibody conjugated to HRP. The blots were
developed using the enhanced chemiluminescence system
(Amersham Bioscience, Piscataway, NJ, USA). Protein
loading was evaluated by actin bands visualized with a
mouse monoclonal anti-actin antibody, diluted 1:2,000
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Omis-
sion of a primary antibody was the control for speciWcity of
the reactions, and these always produced negative result.
The immunoreactivity was quantiWed by densitometric
analysis using the Kodak Gel Logic 440 imaging system
(Eastman Kodak Company, Rochester, NY, USA). Inten-
sity of the band of interest was calculated in relation to
intensity of the actin band.
Statistical analysis
The statistical signiWcance was determined by Student’s
t test. The signiWcance level was set at P < 0.05. All sets
of data are presented as means § SEM.
Light-microscopic immunocytochemistry
ImmunoXuorescence was performed on 10-m-thick trans-
verse sections of fresh-frozen muscle biopsies of all the dis-
eases and controls, as described [3, 15, 26, 37, 40], using
the same antibodies that were used for the immunoblots.
Double-immunoXuorescence utilized goat polyclonal anti-
body against Nogo-A/B in combination with one of the123
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or (b) rabbit polyclonal antibody against caveolin-1. To
block non-speciWc binding of an antibody to Fc receptors,
all sections were preincubated with 10% normal goat or
donkey serum [15, 26, 37, 40]. Omission of the primary
antibody or its replacement with non-immune sera or irrele-
vant antibody was the control for staining speciWcity, and
these always produced negative results.
Gold-immuno-electronmicroscopy
Single- and double-labeled gold immuno-electron-micros-
copy were performed on 10-m unWxed frozen sections of
s-IBM biopsies adhered to the bottom of 35-mm Petri
dishes, as described [3, 15, 26, 37, 40]. Two diVerent spe-
cies-speciWc secondary antibodies, conjugated to either 12
or 6 nm gold particles (Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA), were used in this study. The
sections were then processed for EM as previously
described [3, 15, 26, 37, 40].
Combined immunoprecipitation–immunoblotting
To evaluate whether in s-IBM muscle Wbers (a) Nogo
physically associates with BACE1, and (b) BACE1 physi-
cally associates with APP, we performed the combined
immunoprecipitation–immunoblot technique, as described
[15, 37, 40, 41]. In brief, 100 g of total muscle protein
were immunoprecipitated in precipitation-buVer contain-
ing 5 g of IgG antibody against BACE1. The immunopre-
cipitated complex, containing IgG antibody along with its
bound target antigen and all proteins bound to that antigen,
was pulled down using Protein G Sepharose 4 Fast Flow
(Amersham) during 4 h of incubation at 4°C. The solution
was then centrifuged for 5 min (16,000£g at 4°C) and the
supernatant removed. The precipitated sepharose immuno-
complexes were washed three times with the precipitation
buVer by centrifuging 5 min each (16,000£g at 4°C).
Immunoprecipitates were electrophoresed and immuno-
probed with either goat polyclonal anti-Nogo antibody or
mouse monoclonal 6E10 antibody against APP/A, each
followed by an appropriate secondary antibody. To conWrm
speciWcity of the physical association identiWed by the
immunoprecipitation–immunoblot reaction, primary anti-
bodies were omitted from either the immunoprecipitation
or immunoprobing. The same technique was performed to
evaluate whether Nogo physically associates with APP.
Cultured human muscle Wbers
Primary cultures of normal human muscle were established,
as we have described [2], from satellite cells of portions of













































































































































































































































































































































































































































































































































































































520 Acta Neuropathol (2007) 114:517–526were performed, were considered free of muscle disease.
We established 11 culture sets, each from satellite cells
derived from a diVerent muscle biopsy. All experimental
and control conditions were studied on sister cultures in
the same culture set. Not all studies were performed on
every set. Twenty days after myoblasts fused, a 3 Kb 751
APP-cDNA, in either sense or anti-sense orientation, was
transferred into well-diVerentiated myotubes using a repli-
cation-deWcient adenovirus (RDAV) vector at 0.3 £
108 pfu/ml culture medium, as detailed [5, 6, 24]. At the
same time, non-APP-transduced control sister-cultures
were treated for 24 h with either of two ER-stress inducers,
Tunicamycin, an N-glycosylation inhibitor (4 g/ml), or
Thapsigargin, an inhibitor of ER calcium-ATPase (300 nM)
(both inhibitors from Sigma Co, St Louis, MO, USA)
[10, 22, 26]. In our previous studies, both inhibitors
successfully induced ER stress in CHMFs [26, 27].
Four days after APP gene transfer, or 24 h after treatment
with an ER-stress inducer, cultures were processed for
light-microscopic immunocytochemistry, immunoblot and
immunoprecipitation studies of Nogo and BACE1, as
described [15, 26, 41, 43].
Results
Muscle biopsies
Nogo-B and BACE1 are increased in s-IBM muscle Wbers
Antibodies R461 and N-18, which were previously charac-
terized as recognizing both Nogo-A and Nogo-B [1, 17,
18], showed a strongly increased level of 46 kDa Nogo-B
in s-IBM as compared to controls (Fig. 1a). Densitometric
quantiWcation of immunoblots performed on 7 s-IBM and
7 control muscle biopsies revealed that Nogo-B was
increased 2.5-fold (P = 0.025) in s-IBM biopsies compared
to controls (Fig. 1b). Those antibodies R461 and N-18
should also recognize Nogo-A; however, Nogo-A was not
expressed in either normal-control or s-IBM muscle biop-
sies (Fig. 1a). (In our studies, similarly to previous reports
[17, 30], Nogo-A has molecular weight of approximately
180 kDa, which may be due to Nogo-A glycosylation.)
Another Nogo-A speciWc antibody, H-300 (Santa Cruz)
also failed to detect any Nogo-A in these samples; a weak
band corresponding to 80 kDa was non-speciWc (Fig. 1a).
We found that all three of these antibodies did recognize
Nogo-A in a control lysate from human medulloblastoma
cells (TE671) that express Nogo-A (Fig. 1a), and also in
muscle biopsies from patients with peripheral neuropathy
and ALS [42, not shown here]. Together, our results
showed that Nogo-B levels are signiWcantly increased in
s-IBM while Nogo-A is not detectable. The level of RTN3,
another important inhibitor of BACE1 [18], was low in
both s-IBM and control biopsies, and there was no discern-
able diVerence between the two groups (data not shown).
BACE1, which we have previously shown increased
and migrating at 70 kDa in s-IBM muscle Wbers [34, 36],
was, when quantiWed in the current studies, found increased
3.5-fold (P = 0.007) in s-IBM as compared to control
muscle biopsies (Fig. 1c, d).
Detection of protein aggregates containing Nogo-B 
and BACE1 in s-IBM
We used immunohistochemistry to morphologically localize
Nogo-B in s-IBM muscle Wbers. In all of the s-IBM muscle
biopsies, 60–70% of the vacuolated muscle Wbers contained,
mainly in their non-vacuolated cytoplasm, numerous well-
deWned, plaque-like, punctuate or elongated, aggregates
immunoreactive with antibodies R461 and N-18 (Fig. 2a, c,
d, f). As shown above by our immunoblots, these two anti-
bodies in s-IBM muscle recognize exclusively Nogo-B, sug-
gesting that the morphologically evident aggregates contain
Nogo-B. In addition, in all s-IBM muscle biopsies, 20–30%
of the non-vacuolated Wbers (on a given cross-section) con-
tained similar aggregates (Fig. 2b). Nogo-B immunoreactive
aggregates also contained BACE1 (Fig. 2d, e). As both
BACE1 and Nogo-B can be localized in lipid rafts, we
found with an antibody against caveolin-1, that caveolin-1
was associated with some of the Nogo-B aggregates
(Fig. 2f, g). These results appeared speciWc because the anti-
body H-300, which speciWcally recognizes Nogo-A, and did
not detect any speciWc band in s-IBM muscle biopsies on
immunoblots, did not label any aggregates. In contrast to the
staining of Nogo-B in s-IBM biopsies, none of the normal or
disease-control biopsies had muscle Wbers containing Nogo-
B immunoreactive aggregates (data not shown). While
Nogo-A was negative in s-IBM muscle Wbers, it was, as we
have recently reported [42], strongly and diVusely immuno-
reactive in (a) regenerating muscle Wbers in dermatomyositis
and polymyositis, and (b) in denervated muscle Wbers in
amyotrophic lateral sclerosis and peripheral neuropathies
(not shown).
Nogo-B and BACE1 ultrastructurally co-localize 
within s-IBM aggregates
To determine the ultrastructural localization of Nogo-B in
the aggregates, we performed immuno-electronmicroscopic
examination of s-IBM muscle Wbers. Nogo-B was detected
on or very close to the 6–10 nm amyloid-like Wbrils
(Fig. 3a), but was more associated with the cytoplasmic
amorphous material (Fig. 3b). Double-labeling experiments
showed that BACE1 was co-localized with Nogo-B on
6–10 nm Wlaments and on the amorphous material123
Acta Neuropathol (2007) 114:517–526 521(Fig. 3c). Both Nogo-B and BACE1 were also found in the
lipid raft structures that were labeled by the antibody
against caveolin-1 (Fig. 3d,e). Therefore, Nogo-B immuno-
reactive aggregates appear to contain BACE1.
Physical interaction between BACE1 and Nogo-B
Since the ultrastructural results suggest that BACE1 and
Nogo-B co-exist in s-IBM aggregates, we next tested
whether, within s-IBM muscle Wbers, they physically interact
as previously reported in the human brain [18]. Immuno-
precipitation with an antibody against BACE1 followed by
immunoblotting with antibody N-18, which in s-IBM mus-
cle biopsies recognized only Nogo-B, revealed a 46-kDa
band corresponding to Nogo-B. Omission of a primary
antibody against BACE1 from the immunoprecipitation
reaction (denoted by £) or in the immunoblot (denoted by #)
failed to detect Nogo-B (Fig. 4a). The co-immunoprecipitation
Fig. 1 Immunoblots of Nogo-B, Nogo-A and BACE1 of muscle ho-
mogenates of control (C) and s-IBM muscle biopsies. a Demonstrates
that a 46 kDa band of Nogo-B detected with antibodies R461 and N-18
was signiWcantly stronger in s-IBM than in control biopsies; however
a 180 kDa band corresponding to Nogo-A was not demonstrable with
antibodies R461 and N-18, which is considered to recognize both
Nogo-A and -B. (This was conWrmed with an antibody H-300, which
speciWcally recognizes Nogo-A. Nogo-A was not demonstrable in
either control or s-IBM muscle biopsies with this antibody). TE671
indicates immunoblots of an extract of human medulloblastoma cells
that express both Nogo-A and -B. In b immunoreactivity was quantiWed
by densitometric analysis using the Kodak Gel Logic 440 imaging system
(Eastman Kodak Company, Rochester, NY, USA). Intensity of the
band of interest was calculated in relation to the actin band Immuno-
blot in c and its densitometric analysis in d demonstrate that BACE1 is
signiWcantly increased in s-IBM as compared to controls. (Details for
a–d in the text, * indicates P < 0.05)
Fig. 2 ImmunoXuorescence of 




aggregates of Nogo-B. d–g 
Double-label immunoXuores-
cence—the aggregates 
immunoreactive for Nogo-B (d) 
are also immunoreactive for 
BACE1 (e), and aggregates 
immunoreactive for Nogo-B (f) 
are also immunoreactive for 
caveolin-1 (g). a–c £1,100, 
d–g £2,000123
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biopsies BACE1 interacted with APP (Fig. 4b). However,
there was no physical association of Nogo-B with APP/
A (Fig. 4c). Together, these studies indicate that Nogo-B
and BACE1 are present in aggregates where they appear to
have interacted.
Cultured human muscle Wbers
Increased expression of APP enhances Nogo-B 
and BACE1 protein levels
To determine what might be causing increased expression
of Nogo-B and BACE1 in s-IBM muscle Wbers, we utilized
our IBM human culture model, which exhibits several
abnormalities present in s-IBM muscle Wbers [6, 15, 24, 41,
43]. Since increased production and accumulation of APP
and A, as well as ER-stress, seem to be important compo-
nents of the s-IBM pathogenesis, in this study we: (a)
engineered cultured human muscle Wbers (CHMFs) to
overexpress APP through an adenoviral APP cDNA
transfer, and (b) separately induced ER-stress in CHMFs.
Densitometric analysis of immunoblots demonstrated
that in the APP-overexpressing CHMFs (lane APP+)
compared to controls (Fig. 5a, b) a 46 kDa band corre-
sponding to Nogo-B was increased 1.3-fold (P = 0.018) and
Nogo-A was increased 1.7 fold (P = 0.038). APP over-
expression in CHMFs also caused 1.9-fold (P = 0.022)
Fig. 3 Single (a, b) and double-label (c, d, e) gold-immuno-electron-
microscopy of s-IBM muscle Wbers. a, b Nogo-B (12 nm gold parti-
cles) is localized on 6–10 nm Wlaments (a) and a large amorphous
inclusion (b); on the right of b is a normal myoWbrillar structure that
does not contain immunoreactive Nogo-B. c Nogo-B (12 nm gold par-
ticles) and BACE1 (6 nm gold particles) are associated with 6–10 nm
amyloid-like Wbrils and with amorphous-Xoccular material. d both
Nogo-B (12 nm gold particles) and BACE1 (6 nm gold particles) are
immunolocalized in the caveolae structures, and on 6–10 nm Wlaments.
e Double-labeling of a caveola with antibodies against Nogo-B (12 nm
gold particles) and caveolin-1 (6 nm gold particles). a–d £53,000;
c £68,000
Fig. 4 a, b Immunoprecipitations of s-IBM biopsies with anti-BACE1
antibody, followed by immunoprobing with an antibody against Nogo
A/B in a, and with antibody 6E10 against APP/A in b. A strong band
of the appropriate molecular weight of 46 kDa corresponding to Nogo-
B is visible in a. In b, a strong band of 130 kDa corresponds to APP.
£ = omission of the antibody against BACE1 from the immunoprecip-
itation solution; # = omission of the antibody against Nogo-B in a or
omission of the antibody against APP/A (6E10) in b in the immuno-
blotting—these omissions resulted in negative reactions. Together the
data indicate there is a physical interaction between Nogo-B and
BACE1 in s-IBM muscle Wbers. c Illustrates that there is no interaction
between APP/A and Nogo-B123
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These eVects of APP overexpression were speciWc because
overexpressing APP in antisense orientation in CHMFs
did not cause increase of Nogo-B, Nogo-A, or BACE1
(Fig. 5e–h).
Contrarily to APP-overexpression, treatment of
CHMFs with two ER-stress inducers, thapsigargin (Tg) or
tunicamycin (Tm), led to decreased level of Nogo-B (1.3-
fold [P = 0.019] by thapsigargin, and 1.2-fold [P = 0.04]
by tunicamycin), and of Nogo-A (1.4-fold [P = 0.001] by
thapsigargin and 1.5-fold [P = 0.001] by tunicamycin)
(Fig. 5a, b). However, both ER-stress inducers increased
BACE1 levels—1.4-fold (P = 0.027) after thapsigargin
treatment and 1.7-fold (P = 0.011) after tunicamycin treat-
ment (Fig. 5c, d).
By immunoXuorescence, in normal, non-APP-over-
expressing CHMFs, Nogo and BACE1 were weakly and
diVusely immunoreactive (Fig. 6a, b), whereas in the
APP-overexpressing (APP+) cultures their immuno-
reactivities were stronger and occasionally in aggregates
(Fig. 6c, d). (Because CHMFs express both Nogo-B and
Nogo-A, and the antibodies N-18 and R461 that we utilized
for immunostaining recognize both Nogo-A and Nogo-B,
we use term “Nogo” to refer to those two stainings.) In the
aggregates, Nogo and BACE1 co-localized (Fig. 6c, d).
In the CHMFs, interactions of BACE1 with Nogo-B and
Nogo-A (Fig. 7a) or with APP (Fig. 7b) were further con-
Wrmed through our co-immunoprecipitation experiments.
Discussion
In s-IBM muscle Wbers, we demonstrated by immunoblot
analysis, using well-characterized anti-Nogo antibodies,
Fig. 5 Immunoblots performed 
with cultured human muscle 
Wbers (CHMFs). a Immunoblots 
of control—C, Tg- and Tm-
exposed, and APP-overexpress-
ing CHMFs, and their 
densitometric analyses (b), show 
that Nogo-A and -B are signiW-
cantly increased in APP-over-
expressing CHMFs, but both are 
decreased in CHMFs in which 
ER-stress was induced by Tg or 
Tm treatment. c, d BACE1 is 
signiWcantly increased due to 
APP overexpression, or treat-
ment with Tg or Tm. e–h Illus-
trates that overexpressed 
antisense-APP does not inXu-
ence Nogo-A or-B, or BACE1 in 
CHMFs. a–h * indicates 
P < 0.05)
Fig. 6 a–d Double-label immunoXuorescence of “Nogo” (a, c) with
BACE1 (b, d), in the control (a, b) and the APP-overexpressing (c, d)
CHMFs. This illustrates the co-localization of Nogo and BACE1, and
the stronger immunostaining of both due to the APP overexpression.
An upper Wber in c and d contains two large aggregates containing both
Nogo and BACE1. All £1,200123
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virtually undetectable. Our immunocytochemical studies
showed that in s-IBM muscle Wbers Nogo-B was abnor-
mally accumulated multifocally in the form of aggregates
that also contained BACE1 and caveolin-1. By immuno-
electronmicroscopy, both Nogo-B and BACE1 were associ-
ated with the same ultrastructural components, namely,
amorphous material, 6–10 nm amyloid-like Wbrils and
caveolae/lipid-rafts-like structures, which also contained
caveolin-1. Previous studies in other cells have also shown
that Nogo-B and BACE1 are present in the caveolae/lipid-
rafts structures, and processing of APP leading to A
generation is considered to occur in those structures as well
[1, 12, 23, 33].
The two-reticulon family members, RTN3 and Nogo-
B, were previously shown to bind BACE1 in human brain
and in HEK-293 cells [18]. This binding was recently
shown to occur through the C-terminal domain common
to all reticulons and the C-terminal domain of BACE1
[19]. This binding inhibits association of BACE1 with
APP and decreases generation of A-40 and A-42
[18, 19]. Accordingly, within s-IBM muscle Wbers, the
increased Nogo-B and its association with BACE1, might
reXect an attempt by those Wbers to decrease A produc-
tion caused by BACE1-mediated abnormal processing of
APP.
In our cultured human muscle Wbers, APP overexpres-
sion increased both Nogo-B and Nogo-A, as well as the
intracellular amount of BACE1. We propose that the
increased BACE1 is in response to an increased demand to
process the excessive APP, resulting in increased A pro-
duction. Although the mechanism(s) of increased Nogo-B
and -A, in this system needs to be clariWed, we suggest that
they might be to inhibit (at least partially) BACE1 binding
to APP, thereby decreasing production of A and protect-
ing the muscle Wber from the A detrimental inXuence.
Since both Nogo-B and Nogo-A bind to BACE1 in our
CHMFs, we propose that both Nogo isoforms could pro-
tect a muscle Wber from an abnormal accumulation of A;
however, in the s-IBM biopsied muscle Wbers, only Nogo-
B seems to be playing this putative role. Because Nogo-A
is increased in regenerating muscle Wbers [42], it may have
additional roles in those young Wbers. One possibility
might be to help manage the increased APP known to
occur in regenerating muscle Wbers in vivo [4, 29]—this
putative beneWt of Nogo-A could be deWcient in s-IBM
muscle Wbers, since they have diminished regenerative
capabilities, and we could not demonstrate Nogo-A in
them. Nogo-A is predominantly expressed in the central
nervous system, where it is present mainly in oligodendro-
cytes [11, 39]. A recent study demonstrated that Nogo-A,
but not Nogo-B, is increased in hippocampal neurons in
Alzheimer disease (AD) brain, and it also co-localizes with
A deposits in extracellular senile plaques [17]. Similarly
to our present studies, Nogo-A did not physically associ-
ated with APP/A in AD brain [17]; whether Nogo-A
physically associated with BACE1 in AD brain was not
reported [17].
In our cultured human muscle Wbers, ER stress
decreased Nogo-A/B and increased BACE1 levels as com-
pared to the unstressed control. Analogously, we suggest
that in s-IBM muscle Wbers, continuous ER stress [27, 37]
might be reducing the intracellular ratio of Nogo-B to
BACE1 by decreasing Nogo-B and increasing BACE1,
resulting in A continuing to accumulate and exert its cyto-
toxic inXuence.
Conclusions
We report abnormally increased Nogo-B and its multi-focal
accumulation within s-IBM muscle Wbers. We experimen-
tally demonstrate that two diVerent mechanisms, namely
APP overexpression and endoplasmic reticulum stress, are
diVerentially involved in regulation of Nogo-B, Nogo-A
and BACE1 in cultured human muscle Wbers. Since both
APP overexpression and ER-stress are important patho-
logic aspects of the s-IBM muscle Wbers, the same regula-
tory mechanism may operate in them. If so, manipulations
toward increasing Nogo-B and/or interfering with pathways
inducing ER-stress might provide new therapeutic opportu-
nities for s-IBM patients.
Acknowledgments Slawomir Wojcik is on leave from the
Department of Anatomy and Neurobiology, Medical University of
Gdansk, Gdansk, Poland. Maggie Baburyan provided excellent
technical assistance in electronmicroscopy.
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